RAPT Therapeutics Inc (NASDAQ: RAPT)’s stock price has dropped by -2.80 in relation to previous closing price of 1.07. Nevertheless, the company has seen a loss of -18.75% in its stock price over the last five trading days. benzinga.com reported 2024-11-11 that On Monday, Rapt Therapeutics, Inc. RAPT stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program.
Is It Worth Investing in RAPT Therapeutics Inc (NASDAQ: RAPT) Right Now?
The 36-month beta value for RAPT is at 0.11. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 9 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RAPT is 30.55M, and currently, shorts hold a 8.73% of that float. The average trading volume for RAPT on November 21, 2024 was 506.28K shares.
RAPT’s Market Performance
The stock of RAPT Therapeutics Inc (RAPT) has seen a -18.75% decrease in the past week, with a -39.53% drop in the past month, and a -55.36% fall in the past quarter. The volatility ratio for the week is 19.06%, and the volatility levels for the past 30 days are at 17.77% for RAPT. The simple moving average for the past 20 days is -44.57% for RAPT’s stock, with a -79.59% simple moving average for the past 200 days.
Analysts’ Opinion of RAPT
Many brokerage firms have already submitted their reports for RAPT stocks, with Stifel repeating the rating for RAPT by listing it as a “Hold.” The predicted price for RAPT in the upcoming period, according to Stifel is $2 based on the research report published on November 13, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see RAPT reach a price target of $2, previously predicting the price at $8. The rating they have provided for RAPT stocks is “Neutral” according to the report published on November 11th, 2024.
RAPT Trading at -44.10% from the 50-Day Moving Average
After a stumble in the market that brought RAPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.20% of loss for the given period.
Volatility was left at 17.77%, however, over the last 30 days, the volatility rate increased by 19.06%, as shares sank -40.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.08% lower at present.
During the last 5 trading sessions, RAPT fell by -17.19%, which changed the moving average for the period of 200-days by -95.89% in comparison to the 20-day moving average, which settled at $1.8772. In addition, RAPT Therapeutics Inc saw -95.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPT starting from Brockstedt Dirk G., who sale 898 shares at the price of $22.78 back on Jan 05 ’24. After this action, Brockstedt Dirk G. now owns 27,820 shares of RAPT Therapeutics Inc, valued at $20,456 using the latest closing price.
HO WILLIAM, the Chief Medical Officer of RAPT Therapeutics Inc, sale 2,500 shares at $21.68 during a trade that took place back on Dec 21 ’23, which means that HO WILLIAM is holding 15,020 shares at $54,200 based on the most recent closing price.
Stock Fundamentals for RAPT
Current profitability levels for the company are sitting at:
- -21.72 for the present operating margin
- 0.82 for the gross margin
The net margin for RAPT Therapeutics Inc stands at -20.33. The total capital return value is set at -1.17. Equity return is now at value -80.13, with -69.76 for asset returns.
Currently, EBITDA for the company is -125.85 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.90.
Conclusion
In conclusion, RAPT Therapeutics Inc (RAPT) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
